Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing
Dominic J Hare, Noel G Faux, Blaine R Roberts, Irene Volitakis, Ralph N Martins, Ashley I Bush
METALLOMICS | ROYAL SOC CHEMISTRY | Published : 2016
We examined serum and erythrocyte lead and manganese levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL), which contains over 1000 registrants including over 200 cases of Alzheimer's disease (AD) and 100 mildly cognitively impaired (MCI) individuals. After correcting for confounding effects of age, collection site and sex, we found a significant decrease in serum manganese levels in AD subjects compared to healthy controls. Analysis of smaller subset of erythrocytes revealed no difference in either lead or manganese levels in AD. Although lead and manganese have neurotoxic effects and may be involved in AD pathology, our results showed that neither meta..View full abstract
We wish to thank the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (http://www.aibl.csiro.au/), including all scientists, participants and their families. This work was supported by the Cooperative Research Centre for Mental Health and by Operational Infrastructure Support from the Victorian State Government.